Base de dados : LILACS
Pesquisa : D03.633.100.759.160 [Categoria DeCS]
Referências encontradas : 115 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 12 ir para página                         

  1 / 115 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Araujo, E. G
Texto completo
Id: biblio-1131480
Autor: Brandstetter, L. R. G; Pedroso, A. C. B. R; Oliveira, H. F; Moura, V. M. B. D; Araújo, E. G.
Título: Brief topical and intraluminal use of Carolina rinse solution does not attenuate experimental ischemia and reperfusion injury in rabbit jejunum / [O uso tópico breve e intraluminal da solução de Carolina rinse não atenua a injúria de isquemia e reperfusão experimental no jejuno de coelhos ]
Fonte: Arq. bras. med. vet. zootec. (Online);72(4):1321-1328, July-Aug. 2020. ilus.
Idioma: en.
Resumo: Fifteen New Zealand adult rabbits were randomly allocated into three groups: Sham-operated (group A), Ischemia and Reperfusion (group B) and Carolina Rinse Solution (CRS) (group C). Groups B and C were subjected to one hour of ischemia and two hours of reperfusion. In group C, ten minutes before reperfusion, the bowel lumen was filled with CRS, and the segment immersed in CRS. Necrosis and loss of integrity of the villi were visible in groups B and C. Edema of the submucosa and circular muscle was observed in all groups. Hemorrhage was observed in different layers for groups B and C, but group C showed more severe hemorrhage in different layers during reperfusion. All groups showed polymorphonuclear leukocyte infiltration on the base of the mucosa, submucosa, and longitudinal muscle, in addition to polymorphonuclear leukocytes margination in the mucosal and submucosal vessels. Necrosis of enterocytes, muscles, crypts of Lieberkühn and myenteric plexus was observed in groups B and C during reperfusion. Topical and intraluminal Carolina Rinse Solution did not attenuate the effects of ischemia and reperfusion in the small intestine of rabbits.(AU)

Quinze coelhos da raça Nova Zelândia foram alocados em três grupos: instrumentado (grupo A), isquemia e reperfusão (grupo B) e solução de Carolina rinse (CRS) (grupo C). Os grupos B e C foram submetidos a uma hora de isquemia e a duas horas de reperfusão. No grupo C, 10 minutos antes da reperfusão, o segmento isolado foi imerso e teve seu lúmen preenchido com CRS. Os grupos B e C apresentaram necrose e perda progressiva da integridade das vilosidades. Foi observado edema na submucosa e na camada muscular circular em todos os grupos. Nos grupos B e C, foi observada hemorragia em diferentes camadas, mas, no grupo C, a hemorragia foi mais intensa durante a reperfusão. Todos os grupos apresentaram infiltrado de PMN na base da mucosa, na submucosa e na camada muscular longitudinal e marginação de PMN nos vasos da mucosa e da submucosa. Durante a reperfusão, foi observada necrose dos enterócitos, das camadas musculares, das criptas de Lieberkühn e do plexo mioentérico nos grupos B e C. O uso tópico e intraluminal de CRS não atenuou os efeitos da isquemia e da reperfusão no intestino delgado de coelhos.(AU)
Descritores: Reperfusão/veterinária
Alopurinol/administração & dosagem
Desferroxamina/administração & dosagem
Glutationa/administração & dosagem
Isquemia/veterinária
Jejuno/cirurgia
Limites: Animais
Coelhos
Responsável: BR68.1 - Biblioteca Virginie Buff D'Ápice


  2 / 115 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Cuba
Texto completo
Id: biblio-1125004
Autor: González Escudero, Mabel; Pérez Acosta, Noel David; Roque Pérez, Lázaro.
Título: Síndrome de DRESS secundario a alopurinol / DRESS syndrome secondary to allopurinol
Fonte: Medicentro (Villa Clara);24(2):430-443, abr.-jun. 2020. graf.
Idioma: es.
Resumo: RESUMEN El síndrome de hipersensibilidad por fármacos, también conocido como síndrome de DRESS, es una farmacodermia grave que se caracteriza por una erupción polimorfa diseminada, fiebre y compromiso multiorgánico. Este padecimiento tiene una incidencia que oscila entre el 0,1 % y el 0,01 % de las exposiciones farmacológicas, con una probabilidad de fallecimiento de un 20 % al 30 %. Fue descrito por primera vez en el año 1936, como una reacción adversa a la fenitoína. En la actualidad se reconoce que puede estar asociado a otros fármacos como: abacavir, metronidazol, doxiciclina, isoniazida, carbamacepina, fenobarbital, beta-bloqueadores, dapsona, ranitidina, antiinflamatorios no esteroideos y el alopurinol. Se presenta un paciente de 69 años de edad que desarrolló un síndrome de DRESS secundario a alopurinol. El paciente mostró signos poco frecuentes de esta rara enfermedad: linfocitos atípicos, hepatomegalia y afección renal; falleció poco después debido a un choque séptico por estafilococo áureo.

ABSTRACT Drug hypersensitivity syndrome, also known as DRESS syndrome, is a severe pharmacodermia characterized by a polymorphous disseminated rash, fever, and multi-organ involvement. Its incidence ranges between 0.1 to 0.01% from the pharmacological exposures, with a probability of death ranging from 20 to 30%. It was first described in 1936 as an adverse reaction to phenytoin. Nowadays, it is known that it can also be associated with other drugs such as abacavir, metronidazole, doxycycline, isoniazid, carbamazepine, phenobarbital, beta-blockers, dapsone, ranitidine, nonsteroidal anti-inflammatory drugs and allopurinol. We present a 69-year-old male patient who developed a DRESS syndrome secondary to alupurinol. The patient showed unusual signs of this rare disease such as atypical lymphocytes, hepatomegaly and kidney disease; he dies shortly after from a septic shock due to Staphylococcus aureus.
Descritores: Alopurinol/efeitos adversos
Síndrome de Hipersensibilidade a Medicamentos
Responsável: CU425.1 - Centro Provincial de Información de Ciencias Médicas de Villa Clara


  3 / 115 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-886234
Autor: Akahane, Hugo Genki Kagawa; Gomes, Ricardo Zanetti; Paludo, Katia Sabrina; Linhares, Filipe; Lopes, Luana.
Título: The influence of allopurinol and post-conditioning on lung injuries induced by lower-limb ischemia and reperfusion in Wistar rats
Fonte: Acta cir. bras;32(9):746-754, Sept. 2017. tab, graf.
Idioma: en.
Resumo: Abstract Purpose: To analyze the effects of allopurinol and of post-conditioning on lung injuries induced by lower-limb ischemia and reperfusion. Methods: Thirty rats were used. They were divided in 5 groups: (1) group A: abdominal aortic dissection only, (2) group B: ischemia and reperfusion, (3) group C: administered allopurinol (100mg/Kg) a few hours before procedure, (4) group D: post-conditioned and (5) group E: administered allopurinol and post-conditioned. With the exception of group A, all groups were submitted to infrarenal aortic ischemia for 2 hours, and reperfusion for 72 hours. After euthanasia, lungs were removed for histological analysis. They were graded under two scores: pulmonary injury (neutrophil infiltration, interstitial edema, vascular congestion, and destruction of lung architecture) and lymphocytic score (neutrophil infiltration, lymphoid aggregate and secondary follicle). Results: On the pulmonary injury score, the degree of injury was smaller than in groups D and E, when compared to group B, p<0.05. Group C did not obtain the same result (p>0,05). On the lymphocytic score, there was no statistic difference among groups, p>0.05. Conclusion: Both post-conditioning and the combination of allopurinol and post-conditioning were effective in remote lung protection induced by lower-limbs I/R. When used in isolation, allopurinol showed no protective effect.
Descritores: Traumatismo por Reperfusão/complicações
Alopurinol/uso terapêutico
Lesão Pulmonar/prevenção & controle
Pós-Condicionamento Isquêmico
-Ratos Wistar
Modelos Animais de Doenças
Lesão Pulmonar/etiologia
Antimetabólitos/uso terapêutico
Limites: Animais
Masculino
Feminino
Ratos
Responsável: BR1.1 - BIREME


  4 / 115 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-886210
Autor: Özer, Nazmi; Bülbüloğlu, Ertan; Yormaz, Serdar; Ece, İlhan.
Título: Evaluation of silybum marinaum efficacy on University of Wisconsin and histidine-tryptophan-ketoglutarate solutions latter the damage of the perfused liver
Fonte: Acta cir. bras;32(6):407-417, June 2017. tab, graf.
Idioma: en.
Resumo: Abstract Purpose: To investigate the hepatoprotective and antioxidant effeicacies of Silybum marianum's (silymarin, S) on University of Wisconsin (UW) and histidinetryptophan-ketoglutarate (HTK) preservation solutions. Methods: Thirty two Wistar albino adult male rats were used. Group 1: UW group, Group 2: UW + Silymarin group(S), Group 3: HTK group, Group 4: HTK + silymarin group (S), respectively. Silymarin was enforced intraperitoneally before the surgery. Biopsies were enforced in 0, 6 and 12.hours to investigate. Results: Biochemical parameters examined in alanine aminotransferase (ALT), furthermore superoxide dismutase (SOD), catalase (CAT), and malondialdehyde (MDA) in rats were also evaluated. Detected histopathological changings were substantially declining in the groups that received silymarin, cellular damage was decreased significantly in HTK + Silymarin group, according to other groups. It has been identified as the most effective group was HTK + silymarin group in evaluation of ALT, electron microscopic results, also decreased MDA and elevated in SOD, and CAT activity. Caspase 3 analysis showed a substantial lower apoptosis ratio in the silymarin groups than in the non-performed groups (p<0.05). Conclusion: Histidinetryptophan-ketoglutarate+silymarin group provides better hepatoprotection than other groups, by decreasing the hepatic pathologic damage, delayed changes that arise under cold ischemic terms.
Descritores: Silimarina/uso terapêutico
Soluções para Preservação de Órgãos
Substâncias Protetoras/uso terapêutico
Doença Hepática Induzida por Substâncias e Drogas/tratamento farmacológico
Antioxidantes/uso terapêutico
-Cloreto de Potássio
Procaína
Rafinose
Imuno-Histoquímica
Adenosina
Alopurinol
Ratos Wistar
Modelos Animais de Doenças
Glucose
Glutationa
Insulina
Manitol
Limites: Animais
Masculino
Ratos
Responsável: BR1.1 - BIREME


  5 / 115 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-989063
Autor: Laçin, Nihat; İzol, Bozan Serhat; Özkorkmaz, Ebru Gökalp; Deveci, Buşra; Tuncer, Mehmet Cudi.
Título: The effect of graft application and allopurinol treatment on calvarial bone defect in rats
Fonte: Acta cir. bras;34(3):e201900306, 2019. tab, graf.
Idioma: en.
Resumo: Abstract Purpose: To investigate the effects of allopurinol administration on osteoinductive reaction and bone development with graft material. Methods: Thirty-six Wistar albino rats were divided into 3 groups. In the control group, calvarial bone defect was only created without any treatment. In the Defect + Graft group, allograft treatment was performed by forming 8 mm calvarial bone defect. In the Defect + Graft + Allopurinol group, alloplastic bone graft was placed in the calvarial bone defect and then, allopurinol (50 mg/kg/day) treatment was intraperitoneally applied for 28 days. Results: Histopathological examination revealed inflammation, congestion in the vessels, and an increase in osteoclast cells in the defect area. We also observed that new osteocyte cells, increase in connective tissue fibers, and new bone trabeculae. Osteopontin expression was positive in osteoblast cells and lacunated osteocyte cells were located in the periphery of the new bone trabeculae. Osteopontin expression was also positive in osteoblasts and osteocytes cells of new bone trabeculae in the graft site. Conclusion: It has been shown that allopurinol treatment in rat calvaria defects may induce osteoblastic activity, matrix development, mature bone cell formation and new bone formation when used with autogenous grafts.
Descritores: Osteogênese/efeitos dos fármacos
Crânio/efeitos dos fármacos
Cicatrização/efeitos dos fármacos
Regeneração Óssea/efeitos dos fármacos
Alopurinol/farmacologia
-Crânio/lesões
Ratos Wistar
Modelos Animais de Doenças
Autoenxertos
Limites: Animais
Ratos
Responsável: BR1.1 - BIREME


  6 / 115 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-777094
Autor: Zhou, Jiang-qiao; Qiu, Tao; Zhang, Lu; Chen, Zhong-bao; Wang, Zhi-shun; Ma, Xiao-xiong; Li, Dongyu.
Título: Allopurinol preconditioning attenuates renal ischemia/reperfusion injury by inhibiting HMGB1 expression in a rat model
Fonte: Acta cir. bras;31(3):176-182, Mar. 2016. graf.
Idioma: en.
Projeto: National Natural Science Foundation of China; . Hubei Natural Science Foundation; . bureau of public health of Hubei Province; . Wuhan Municipal Science and Technology Bureau.
Resumo: ABSTRACT PURPOSE: To investigate the potential effects of pretreatment with allopurinol on renal ischemia/reperfusion injury (IRI) in a rat model. METHODS: Twenty four rats were subjected to right kidney uninephrectomy were randomly distributed into the following three groups (n=8): Group A (sham-operated group); Group B (ischemic group) with 30 min of renal ischemia after surgery; and Group C (allopurinol + ischemia group) pretreated with allopurinol at 50 mg/kg for 14 days. At 72 h after renal reperfusion, the kidney was harvested to assess inflammation and apoptosis. RESULTS: Pretreatment with allopurinol significantly improved renal functional and histological grade scores following I/R injury (p<0.05). Compared with Group B, the expression levels of caspase-3 and Bax were markedly reduced in Group C, meanwhile, whereas expression of bcl-2 was clearly increased (p<0.05). A newly described marker of inflammation, High Mobility Group Box 1(HMGB1), showed reduced expression in Group C (p<0.05). CONCLUSION: Pretreatment with allopurinol had a protective effect on kidney ischemia/reperfusion injury, which might be related to the inhibition of HMGB1 expression.
Descritores: Traumatismo por Reperfusão/prevenção & controle
Alopurinol/farmacologia
Precondicionamento Isquêmico/métodos
Substâncias Protetoras/farmacologia
Proteína HMGB1/efeitos dos fármacos
Rim/irrigação sanguínea
-Superóxido Dismutase/efeitos dos fármacos
Nitrogênio da Ureia Sanguínea
Traumatismo por Reperfusão/metabolismo
Distribuição Aleatória
Ratos Sprague-Dawley
Apoptose/efeitos dos fármacos
Peroxidase/metabolismo
Proteína HMGB1/metabolismo
Modelos Animais de Doenças
Inflamação/metabolismo
Rim/patologia
Limites: Animais
Masculino
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME


  7 / 115 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-775566
Autor: Gomes, Ricardo Zanetti; Romanek, Gabriela Moreira Mahle; Przybycien, Michella; Amaral, Danielli Cristina; Akahane, Hugo Genki Kagawa.
Título: Evaluation of the effect of allopurinol as a protective factor in post ischemia and reperfusion inflammation in Wistar rats
Fonte: Acta cir. bras;31(2):126-132, Feb. 2016. tab, graf.
Idioma: en.
Resumo: PURPOSE: To investigate the potential protective effect of allopurinol on reperfusion injury by determining the inflammatory response through the measurement of tumor necrosis factor-alpha (TNF-alpha). METHODS: Sixty rats were distributed into two groups: control and allopurinol and each group was divided into three subgroups, ischemia for two hours, ischemia for three hours and ischemia simulation. Allopurinol group rats received 100mg/kg dose of allopurinol, whereas control group rats received an equivalent dose of saline. Clamping of the infrarenal aorta was performed for two or three hours depending on the subgroup. Ischemia simulation subgroups did not suffer ischemia, just aortic dissection, and maintenance for three hours. After 72 hours of reperfusion, blood was collected by cardiac puncture for TNF-alpha measurement. RESULTS: Allopurinol reduced TNF-alpha significantly (p <0.001) when compared to the matching control subgroups (control X allopurinol in ischemia for two hours and for three hours). CONCLUSION: Allopurinol reduced the concentrations of serum TNF-alpha when used at different times of ischemia followed by reperfusion, which might indicate reduction of the inflammation provoked by the reperfusion injury.
Descritores: Traumatismo por Reperfusão/metabolismo
Alopurinol/farmacologia
Cavidade Abdominal/irrigação sanguínea
Isquemia/cirurgia
Antimetabólitos/farmacologia
-Fatores de Tempo
Traumatismo por Reperfusão/prevenção & controle
Distribuição Aleatória
Fator de Necrose Tumoral alfa/análise
Fator de Necrose Tumoral alfa/efeitos dos fármacos
Espécies Reativas de Oxigênio/metabolismo
Ratos Wistar
Modelos Animais
Inflamação/metabolismo
Limites: Animais
Responsável: BR1.1 - BIREME


  8 / 115 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-947217
Autor: Madruga, G; Ribeiro, A. P; Ruiz, T; Sousa, V. R. F; Campos, C. G; Almeida, A. B. P. F; Pescador, C. A; Dutra, V.
Título: Ocular manifestations of leishmaniasis in a cat: first case report from Brazil / Manifestações oculares da leishmaniose em um gato: primeiro relato de caso do Brasil
Fonte: Arq. bras. med. vet. zootec. (Online);70(5):1514-1520, set.-out. 2018. ilus.
Idioma: en.
Resumo: An 8-year-old domestic short hair female cat initially presented with bilateral uveitis with pseudotumoral appearance. The patient tested negative for feline immunodeficiency virus (FIV), feline leukemia virus (FeLV) and Toxoplasma gondii. Histopathology of a granulomatous lesion on the upper left conjunctiva revealed amastigotes compatible with Leishmania spp. Aqueous humor was aspired and the diagnosis was confirmed after isolation of promastigotes cultivated in biphasic NNN medium and by positive polymerase chain reaction (PCR) for Leishmania infantum. Treatment with allopurinol (10mg/kg/ BID/PO) was commenced and a natural insect repellent was prescribed. Six months of treatment with allopurinol associated with the initial topical medications helped to improve ocular signs. Leishmaniasis should be considered as a differential diagnosis in cats presenting uveitis with pseudotumoral appearance. To our knowledge, this is the first report of feline leishmaniasis with ocular manifestation in Brazil, in which diagnosis was confirmed by aqueous humor analysis.(AU)

Uma gata, sem raça definida, de oito anos de idade, foi atendida inicialmente com uveíte bilateral, com aparência pseudotumoral em íris. Foi realizado teste para o vírus da imunodeficiência felina (FIV), da leucemia felina (FeLV) e de Toxoplasma gondii, obtendo-se resultados negativos. O exame histopatológico da conjuntiva superior do olho esquerdo revelou amastigotas compatíveis com Leishmania spp. Foi realizada paracentese, e promastigotas foram isoladas no humor aquoso, cultivadas em meio NNN bifásica. Reação em cadeia da polimerase (PCR) confirmou diagnóstico positivo para Leishmania infantum. Tratamento com alopurinol (10mg/kg/BID/PO) foi iniciado, e um repelente natural de insetos foi prescrito. Seis meses de tratamento com alopurinol associado aos medicamentos tópicos iniciais ajudaram a melhorar os sinais oculares. Leishmaniose deve ser considerada como um diagnóstico diferencial nos gatos que apresentam uveíte com aparência pseudotumoral de íris. Até o presente momento, este é o primeiro relato de leishmaniose felina com manifestação exclusivamente ocular da doença no Brasil cujo diagnóstico foi confirmado por meio de análise de humor aquoso.(AU)
Descritores: Gatos/microbiologia
Leishmania infantum/microbiologia
Uveíte/diagnóstico
-Alopurinol
Limites: Animais
Gatos
Responsável: BR68.1 - Biblioteca Virginie Buff D'Ápice


  9 / 115 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Cançado, Eduardo Luiz Rachid
Texto completo
Id: biblio-905231
Autor: Guedes, Ana Luiza Vilar; Andrade, Adriana Ribas; Nunes, Vinicius Santos; Lima, Fabiana Roberto; Mello, Evandro Sobroza de; Ono, Suzane Kioko; Terrabuio, Débora Raquel Benedita; Cançado, Eduardo Luiz Rachid.
Título: Histological remission of autoimmune hepatitis after the addition of allopurinol and azathioprine dose reduction
Fonte: Autops. Case Rep;7(2):35-42, Apr.-June 2017. ilus.
Idioma: en.
Resumo: The standard therapy for some autoimmune diseases consists of a combination of corticosteroids and thiopurines. In non-responders to thiopurine drugs, the measurement of the metabolites of azathioprine, 6-thioguanine, and 6-methylmercaptopurine, can be a useful tool. The measurement has been used during the treatment of inflammatory bowel diseases and, less commonly, in autoimmune hepatitis. Many patients preferentially metabolize thiopurines to 6-methylmercaptopurine (6-MMP), which is potentially hepatotoxic, instead of 6-thioguanine, the active immunosuppressive metabolite. The addition of allopurinol shifts the metabolism of thiopurine towards 6-thioguanine, improving the immunosuppressive effect. We present the case of a 51-year-old female with autoimmune hepatitis who had a biochemical response after azathioprine and prednisone treatment without histological remission, and who preferentially shunted to 6-MMP. After the addition of allopurinol, the patient's 6-thioguanine levels increased, and she reached histological remission with a reduction of 67% of the original dose of azathioprine. The patient did not develop clinical manifestations as a consequence of her increased immunosuppressive state. We also review the relevant literature related to this issue. In conclusion, the addition of allopurinol to thiopurine seems to be an option for those patients who do not reach histological remission and who have a skewed thiopurine metabolite profile.
Descritores: Alopurinol/administração & dosagem
Azatioprina/administração & dosagem
Hepatite Autoimune/tratamento farmacológico
Indução de Remissão/métodos
-Alopurinol/metabolismo
Azatioprina/administração & dosagem
Limites: Humanos
Feminino
Pessoa de Meia-Idade
Tipo de Publ: Relatos de Casos
Responsável: BR26.7 - Serviço de Biblioteca e Documentação Científica


  10 / 115 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-877105
Autor: Guimarães, Flávio Manuel Gomes.
Título: Tratamento da Gota na Atenção Primária à Saúde / Treatment of Gout in the Primary Health Care / Tratamiento de la Gota en la Atención Primaria de la Salud
Fonte: Rev. bras. med. fam. comunidade;12(39):1-8, jan.-dez. 2017. ilus.
Idioma: pt.
Resumo: Objetivo: O objetivo desta revisão é fornecer informação atualizada e orientações práticas sobre a abordagem da gota na Atenção Primária à Saúde. Métodos: Foram pesquisadas normas de orientação clínica, revisões sistemáticas, meta-análises e estudos originais publicados entre 1 janeiro de 2011 e 31 dezembro de 2016, nas línguas inglesa, portuguesa e espanhola. Resultados: Os fármacos de primeira linha no tratamento da gota aguda são os anti-inflamatórios não esteroides, a colchicina e os corticoides, em monoterapia ou associação. Na gota crônica são usados hipouricemiantes, sendo a primeira linha o alopurinol. O febuxostate e os uricosúricos são alternativas ao alopurinol em casos de intolerância ou ineficácia. A profilaxia das crises de gota agudas está recomendada quando se inicia o tratamento hipouricemiante durante pelo menos 6 meses. Conclusão: A abordagem correta da gota deve fazer parte das competências de um médico especialista em Atenção Primária à Saúde de modo a prestar cuidados adequados à comunidade.

Objective: The objective of this review is to provide updated information and practical guidelines on the approach of gout in Primary Health Care. Methods: We conducted a survey of clinical guidelines, systematic reviews, meta-analyses and original studies published between January 1, 2011 and December 31, 2016 in the English, Portuguese and Spanish languages. Results: First-line drugs in the treatment of acute gout are non-steroidal anti-inflammatory drugs, colchicine and corticosteroids, in monotherapy or combination. In chronic gout, the first-line of hypouricemic therapy is allopurinol. Febuxostat and uricosurics are alternatives to allopurinol in cases of intolerance or ineffectiveness. The prophylaxis of acute attacks is recommended when starting hypouricemic treatment for at least 6 months. Treatment of asymptomatic hyperuricemia is not recommended. Conclusion: The correct approach to gout should be part of the skills of a Primary Care physician in order to provide adequate care to the community.

Objetivo: El objetivo es proporcionar información actualizada y orientación práctica sobre la terapéutica de la gota en la Atención Primaria de Salud. Métodos: Se estudiaron las guías clínicas, revisiones sistemáticas, meta-análisis y estudios originales publicados entre el 1 de enero de 2011 y el 31 de diciembre de 2016, en el inglés, portugués y español. Resultados: Los fármacos de primera línea en el tratamiento de la gota aguda son anti-inflamatorios no-esteroides, la colchicina y los corticosteroides, solos o en combinación. En la gota crónica son utilizados hipouricemiantes, y el alopurinol es lo fármaco de primera línea. Febuxostat y uricosúricos son alternativas al alopurinol en los casos de intolerancia o ineficacia. Se recomienda la profilaxis de las crisis agudas en el tratamiento hipouricemiante durante al menos 6 meses. No se recomienda el tratamiento de la hiperuricemia asintomática. Conclusión: La terapéutica de la gota debe formar parte de las competencias de un médico especialista en Atención Primaria de Salud a fin de proporcionar la atención adecuada a la comunidad.
Descritores: Gota/diagnóstico
Gota/terapia
Atenção Primária à Saúde
-Corticosteroides/uso terapêutico
Alopurinol/uso terapêutico
Anti-Inflamatórios não Esteroides
Colchicina/uso terapêutico
Febuxostat/uso terapêutico
Uricosúricos/uso terapêutico
Tipo de Publ: Revisão
Responsável: BR1931.9 - SBMFC - Sociedade Brasileira de Medicina de Família e Comunidade



página 1 de 12 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde